Related Experiment Video
Updated: Jun 1, 2026

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
Published on: May 20, 2019
Diffuse alveolar hemorrhage
Brandi R Newsome1, Juan E Morales
1University of South Carolina, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Palmetto Health Richland, Columbia, SC, USA.
Abstract:
Diffuse alveolar hemorrhage (DAH) is a life-threatening disorder characterized clinically by the presence of hemoptysis, falling hematocrit, diffuse pulmonary infiltrates and hypoxemic respiratory failure. It refers to bleeding that originates in the pulmonary microvasculature instead of the parenchyma or bronchial circulation. DAH should be considered a medical emergency due to the morbidity and mortality associated with failure to treat the disorder promptly. Pulmonary renal syndromes, connective tissue disorders and drugs make up the majority of the cases of DAH. The treatment of DAH ranges from supportive care and withdrawal of offending drugs to high-dose steroids, immunosuppresents and plasmapharesis. The following review will discuss the clinical, radiographic and pathologic findings in a variety of disorders that cause DAH. Standard treatment options, as well as new treatment options will also be discussed.
Related Concept Videos
Atelectasis II: Pathophysiology
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Hemorrhagic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Pulmonary Embolism I: Introduction
Pulmonary Edema II: Pathophysiology
